Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach

被引:15
作者
Arillotta, Davide [1 ]
Floresta, Giuseppe [2 ]
Pelletier, G. Duccio Papanti [3 ]
Guirguis, Amira [4 ]
Corkery, John Martin [5 ]
Martinotti, Giovanni [6 ,7 ]
Schifano, Fabrizio [5 ]
机构
[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Sect Pharmacol & Toxicol, I-50121 Florence, Italy
[2] Univ Catania, Dept Drug & Hlth Sci, I-95125 Catania, Italy
[3] Tolmezzo Community Mental Hlth Ctr, ASUFC Mental Hlth Dept, Via Giuliano Bonanni 2, I-33028 Tolmezzo, Italy
[4] Swansea Univ, Fac Med Hlth & Life Sci, Pharm, Singleton Campus, Swansea SA2 8PP, Wales
[5] Univ Hertfordshire, Psychopharmacol Drug Misuse & Novel Psychoact Subs, Coll Lane Campus, Hatfield AL10 9AB, England
[6] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, I-66100 Chieti, Italy
[7] Univ G dAnnunzio, Inst Adv Biomed Technol ITAB, Ctr Adv Studies & Technol CAST, Via Vestini 21, I-66100 Chieti, Pescara, Italy
关键词
GLP-1 receptor agonists; semaglutide; mental health; craving; substance; addiction; food noise; shopping; sex; social media; GLUCAGON-LIKE PEPTIDE-1; WEIGHT-LOSS; DRUG; FOOD;
D O I
10.3390/brainsci14060617
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways related to appetitive behavior. Hence, this study explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on substance and behavioral addictions, including alcohol, caffeine, nicotine, cannabis, psychostimulants, compulsive shopping, and sex drive/libido. Data were collected from various social platforms. Keywords related to GLP-1 RAs and substance/behavioral addiction were used to extract relevant comments. The study employed a mixed-methods approach to analyze online discussions posted from December 2019 to June 2023 and collected using a specialized web application. Reddit entries were the focus here due to limited data from other platforms, such as TikTok and YouTube. A total of 5859 threads and related comments were extracted from six subreddits, which included threads about GLP-1 RAs drugs and associated brand names. To obtain relevant posts, keywords related to potential substance use and compulsive behavior were selected. Further analysis involved two main steps: (1) manually coding posts based on users' references to the potential impact of GLP-1 RAs on substance use and non-substance habits, excluding irrelevant or unclear comments; (2) performing a thematic analysis on the dataset of keywords, using AI-assisted techniques followed by the manual revision of the generated themes. Second, a thematic analysis was performed on the keyword-related dataset, using AI-assisted techniques followed by the manual revision of the generated themes. In total, 29.75% of alcohol-related; 22.22% of caffeine-related; and 23.08% of nicotine-related comments clearly stated a cessation of the intake of these substances following the start of GLP-1 RAs prescription. Conversely, mixed results were found for cannabis intake, and only limited, anecdotal data were made available for cocaine, entactogens, and dissociative drugs' misuse. Regarding behavioral addictions, 21.35% of comments reported a compulsive shopping interruption, whilst the sexual drive/libido elements reportedly increased in several users. The current mixed-methods approach appeared to be a useful tool in gaining insight into complex topics such as the effects of GLP-1 RAs on substance and non-substance addiction-related disorders; some GLP-1 RA-related mental health benefits could also be inferred from here. Overall, it appeared that GLP-1 RAs may show the potential to target both substance craving and maladaptive/addictive behaviors, although further empirical research is needed.
引用
收藏
页数:17
相关论文
共 101 条
[1]   Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future [J].
Alomar, Muaed ;
Tawfiq, Ali M. ;
Hassan, Nageeb ;
Palaian, Subish .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
[2]   Semaglutide and beyond: a turning point in obesity pharmacotherapy [J].
不详 .
LANCET REGIONAL HEALTH-EUROPE, 2024, 37
[3]   GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach [J].
Arillotta, Davide ;
Floresta, Giuseppe ;
Guirguis, Amira ;
Corkery, John Martin ;
Catalani, Valeria ;
Martinotti, Giovanni ;
Sensi, Stefano L. ;
Schifano, Fabrizio .
BRAIN SCIENCES, 2023, 13 (11)
[4]   COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis [J].
Arillotta, Davide ;
Guirguis, Amira ;
Corkery, John Martin ;
Scherbaum, Norbert ;
Schifano, Fabrizio .
BRAIN SCIENCES, 2021, 11 (07)
[5]   After obesity drugs' success, companies rush to preserve skeletal muscle [J].
Arnold, Carrie .
NATURE BIOTECHNOLOGY, 2024, 42 (03) :351-353
[6]   Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683
[7]   Use of glucagon-like peptide-1 receptor agonists in eating disorder populations [J].
Bartel, Sara ;
Mcelroy, Susan L. ;
Levangie, Danielle ;
Keshen, Aaron .
INTERNATIONAL JOURNAL OF EATING DISORDERS, 2024, 57 (02) :286-293
[8]   The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists [J].
Bendotti, Giulia ;
Montefusco, Laura ;
Lunati, Maria Elena ;
Usuelli, Vera ;
Pastore, Ida ;
Lazzaroni, Elisa ;
Assi, Emma ;
Seelam, Andy Joe ;
El Essawy, Basset ;
Jang, Jun ;
Loretelli, Cristian ;
D'Addio, Francesca ;
Berra, Cesare ;
Ben Nasr, Moufida ;
Zuccotti, GianVincenzo ;
Fiorina, Paolo .
PHARMACOLOGICAL RESEARCH, 2022, 182
[9]   Semaglutide for the treatment of overweight and obesity: A review [J].
Bergmann, Natasha Chidekel ;
Davies, Melanie J. ;
Lingvay, Ildiko ;
Knop, Filip K. .
DIABETES OBESITY & METABOLISM, 2023, 25 (01) :18-35
[10]  
Biswas Som S, 2023, J Pediatr Pharmacol Ther, V28, P576, DOI [10.5863/1551-6776-28.6.576, 10.5863/1551-6776-28.6.576]